DKSH stock reports 4.9 percent first half sales growth

Published on 10/04/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DKSH stock carries a 3.6 percent Core EBIT increase to CHF 163.4 million in H1 2026. Adjusted EPS rose 10.6 percent to CHF 1.56.

Fotorealistisches Verteilzentrum mit Regalen, Paletten und Gabelstapler in Asien — Fotorealistisches Motiv eines asiatischen Warenlagers passt zu DKSH Holding AG, ISIN CH0012684657, Marktexpansions- und Distributionsdienstleister, Illustration mit AI erstellt.

DKSH stock (ISIN CH0126673539) is backed by 4.9 percent net sales growth to CHF 5.5 billion in the first half of 2026. The results, presented on July 17, 2026, also show Core EBIT up 3.6 percent to CHF 163.4 million, according to Yahoo Finance.

Revenue growth reaches a three-year high

DKSH said its first half sales growth was the strongest in three years. The company operates across Healthcare, Consumer Goods, Performance Materials and Technology, with all four business units contributing positively to the period's expansion, according to Yahoo Finance.

The comparison is favorable on earnings per share as well. Corrected first half EPS rose 10.6 percent to CHF 1.56, while Core profit after tax increased 12.9 percent to CHF 112.9 million, according to Yahoo Finance.

Margin investment shapes the next phase

The operating picture is more mixed beneath the sales increase. Core EBIT margin was 3.0 percent, 10 basis points below the first half of 2025, as foreign-exchange effects, marketing spending and upfront investment in new healthcare contracts weighed on profitability.

Management expects Core EBIT in 2026 to be higher than in 2025 and described the new healthcare contracts as a source of future growth. The company also reported free cash flow of CHF 147.7 million and cash conversion of 130.8 percent for the first half of 2026, according to Yahoo Finance.

Analyst target stays above recent valuation

Consensus data published by Investing.com on September 7, 2026, show a Buy rating based on eight analysts, with six Buy ratings and two Holds. The average 12-month price target is CHF 73.50, with a high of CHF 81.00 and a low of CHF 64.00.

Cash generation remains the anchor

For investors, the key tension is clear: sales and adjusted earnings are accelerating, while the 3.0 percent Core EBIT margin still reflects investment and currency pressure. The 130.8 percent cash conversion rate gives DKSH financial flexibility as it pursues healthcare growth and acquisitions.